Table 1

Comparison of participants who had at least one symptomatic event during the 12-month study period to those who had none

nParticipants with at least one
symptomatic episode (n=62)
nParticipants with no documented
symptomatic episode (n=16)
p
Age at enrolment624.4 (3.5–5.2)163.8 (3.6–5.2)0.63
Male sex6232 (51.6)167 (43.8)0.39
LCI at enrolment438.8 (8.3–9.3)88.6 (7.0–10.2)0.71
zFEV1 at enrolment27−0.41 (−1.1 to 0.1)3−0.41 (−1.4 to 0.43)0.54
BMI centile* at enrolment6248.0 (40.1–55.0)1645.4 (33.2–57.6)0.73
Ever hospitalised6235 (55.5)166 (40.0)0.28
Genotype
 Class I–III6260 (96.8)1615 (93.8)0.50
 Class IV–V622 (3.2)161 (6.3)0.50
Maintenance therapy at enrolment
 Hypertonic saline6232 (51.6)166 (37.5)0.40
 Dornase alpha6226 (41.9)167 (43.8)1.00
 Chronic inhaled antibiotics6213 (21.0)165 (31.3)0.51
Sputum/oropharyngeal swab microbiology (ever positive in 12 months prior to study)
 Methicillin sensitive Staphylococcus aureus 6255 (88.7)1613 (81.3)0.42
Pseudomonas aeruginosa 6238 (61.3)168 (50.0)0.57
Haemophilus influenzae 6233 (53.2)167 (43.8)0.58
Stenotrophomonas maltophilia 6213 (21.0)163 (18.8)1.00
 Methicillin-resistant Staphylococcus aureus 6210 (16.1)161 (6.3)0.44
Burkholderia cepacia complex620 (0)162 (12.5)0.04
  • Data are presented as median (IQR) or number (%) as appropriate unless otherwise stated. P values for Wilcoxon rank-sum or Fisher’s exact tests are shown.

  • *Based on CDC growth chart.

  • Data acquired at the enrolment visit are shown.

  • BMI, body mass index; LCI, lung clearance index; zFEV1, z-score for FEV1.